Portfolio News
Sofinnova Capital
Enthera Pharmaceuticals, Boston Children’s Hospital and the University of Milan reveal use of novel pathway to restore pancreatic cell function in diabetes
Related Company
Enthera PharmaceuticalsRelated Deal lead
Silvano SpinelliRelated Deal lead
Graziano SeghezziRelated Strategy
CapitalEnthera Pharmaceuticals, a Sofinnova Partners portfolio company, together with scientific partners Boston Children’s Hospital (Harvard Medical School) and the University of Milan, announced on Feb. 3 a study detailing the discovery of a harmful cellular pathway that causes the death of pancreatic beta cells that make insulin.
Enthera aims to develop a therapeutic to block the pathway to treat type 1 diabetes. The study, published Feb. 3 in Nature Communications, used three mouse models of diabetes, and found protective effects when the pathway was blocked genetically or with an antibody. Studies of human cells and diabetes patients were consistent with the mouse findings.
Data from the study reinforced the idea that the ‘IGFBP3/TMEM219’ apoptosis pathway is a key regulator of pancreatic beta cells and a novel therapeutic target for type 1 diabetes.
“The common thought for type 1 diabetes is that it autoimmune,” said Paolo Fiorina, MD, PhD, Enthera's founder. “But immunotherapy doesn’t completely cure diabetes. We think that dysregulation of beta cell homeostasis also plays a role and that IGFBP3 acts as a ‘betatoxin.’”
Enthera, founded in 2016, is developing biologics based on these discoveries. First-in-human tests of an antibody treatment to block the IGFBP3/TMEM219 pathway could begin as early as September 2022 in Europe.
For more information, read:
The article in Nature Communications
Related News
TISSIUM Advances Clinical Pipeline in Hernia Repair Following First FDA Authorization
Galvanize Therapeutics raises $100 million in oversubscribed Series C financing to transform the treatment of cancer and chronic lung disease
BrightHeart Sets New Standard in Prenatal CHD Screening with Landmark Study Published in Obstetrics & Gynecology
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease